昆藥集團(600422.SH)擬回購註銷27萬股限制性股票
格隆匯12月8日丨昆藥集團(600422.SH)發佈公告,公司2017年限制性股票激勵計劃中部分激勵對象由於擔任公司監事或已離職已不再符合激勵條件,其已獲授但尚未解除限售的限制性股票應由公司回購註銷。
根據公司《激勵計劃(草案)》的相關規定,首次授予的激勵對象李林熙、張文森2人因擔任公司監事,趙劍、李斌、張錫、趙玉倉4人因離職,均不再具備激勵資格,上述6名激勵對象所持有的已授予但尚未解除限售的限制性股票應由公司回購註銷。本次回購註銷限制性股票涉及6人,合計擬回購註銷限制性股票27萬股,註銷日期為2019年12月11日;本次回購註銷完成後,剩餘股權激勵限制性股票200.94萬股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.